Ionis Pharmaceuticals (IONS) Income towards Parent Company (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Income towards Parent Company of -$114.6 million for Q2 2026, down 192.79% year-over-year from $123.6 million in Q2 2025, and down 23.9% quarter-over-quarter from -$92.5 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Income towards Parent Company (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Income towards Parent Company history runs 18 years deep, the most recent figure standing at -$114.6 million for Q2 2026.
- In Q2 2026, Income towards Parent Company fell 192.79% year-over-year to -$114.6 million; the TTM figure through Jun 2026 stood at -$485.3 million (down 171.95% YoY), while the FY2025 annual figure was -$301.5 million, up 17.2% from the prior year.
- Income towards Parent Company for Q2 2026 stood at -$114.6 million, down from -$92.5 million in the prior quarter.
- The five-year high for Income towards Parent Company was $123.6 million in Q2 2025, with the low at -$149.5 million in Q4 2025.
- The 5-year median for Income towards Parent Company is -$98.9 million (2022), against an average of -$74.5 million.
- The sharpest annual moves came in 2023 and 2025: Income towards Parent Company soared 612.46% in 2023, then plunged 925.95% in 2025.
- Ionis Pharmaceuticals' Income towards Parent Company stood at $13.0 million in 2022, then jumped by 612.46% to $92.4 million in 2023, then sank by 115.76% to -$14.6 million in 2024, then slumped by 925.95% to -$149.5 million in 2025, then gained by 23.3% to -$114.6 million in 2026.
- Business Quant data shows IONS's Income towards Parent Company at -$114.6 million in Q2 2026, -$92.5 million in Q1 2026, and -$149.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -114.65 Mn |
| Mar 31, 2026 | -92.53 Mn |
| Dec 31, 2025 | -149.47 Mn |
| Sep 30, 2025 | -128.61 Mn |
| Jun 30, 2025 | 123.55 Mn |
| Mar 31, 2025 | -146.94 Mn |
| Dec 31, 2024 | -14.57 Mn |
| Sep 30, 2024 | -140.48 Mn |
| Jun 30, 2024 | -66.27 Mn |
| Mar 31, 2024 | -142.83 Mn |
| Dec 31, 2023 | 92.45 Mn |
| Sep 30, 2023 | -147.41 Mn |
| Jun 30, 2023 | -85.29 Mn |
| Mar 31, 2023 | -124.34 Mn |
| Dec 31, 2022 | 12.98 Mn |
| Sep 30, 2022 | -47.01 Mn |
| Jun 30, 2022 | -105.18 Mn |
| Mar 31, 2022 | -65.17 Mn |
| Dec 31, 2021 | 210.36 Mn |
| Sep 30, 2021 | -82.47 Mn |